Complete Androgen Insensitivity Syndrome (CAIS) is a condition where a person who is genetically male (46, XY) is resistant to androgens, the hormones responsible for male sex development. This resistance is due to mutations in the androgen receptor (AR) gene on the X chromosome, which prevents the body from responding to androgens like testosterone. Affected individuals have XY chromosomes but develop female external characteristics. Genetically born females (46, XX) can inherit the AR gene mutation and act as carriers but are generally not affected themselves.
Complete Androgen Insensitivity Syndrome (CAIS) is a condition where a person who is genetically male (46, XY) is resistant to androgens, the hormones responsible for male sex development. This resistance is due to mutations in the androgen receptor (AR) gene on the X chromosome, which prevents the body from responding to androgens like testosterone. Affected individuals have XY chromosomes but develop female external characteristics. Genetically born females (46, XX) can inherit the AR gene mutation and act as carriers but are generally not affected themselves.
Complete Androgen Insensitivity Syndrome has an estimated prevalence between 2/100,000 and 5/100,000.
Name | Abbreviation |
---|---|
Previously known as Testicular Feminization Syndrome |
CAIS is caused by mutations in the AR gene on the X chromosome and is inherited in an X-linked recessive manner (see RareShare Guide on Genetic Inheritance). Over 500 different AR mutations have been identified in patients with androgen insensitivity syndrome. 80-100% of CAIS patients have an AR mutation compared to around 16% for partial androgen insensitivity syndrome.The mutation results in the body's cells being completely unable to respond to androgens (male hormones) like testosterone. Androgens like testosterone and dihydrotestosterone are responsible for primary sex characteristics, involving the masculinization of genitals during fetal development, and appearance of secondary sex characteristics like facial hair during puberty. Complete androgen resistance interferes with both processes.
Female external genitalia at birth
Absent or sparse pubic and axillary (armpit) hair
Breast development during puberty
Absent menstruation (primary amenorrhea)
Shallow or absent vagina
Absence of uterus and fallopian tubes
Undescended or absent testes (may be in the abdomen or pelvis)
Tall stature compared to average female height
Lack of acne during puberty
Reduced bone density (osteoporosis risk)
Infertility
Normal to high testosterone levels (but ineffective due to receptor insensitivity)
Elevated estradiol levels (converted from testosterone)
Clinical evaluation: absence of menstruation, absent/delayed puberty, external female genitalia, pelvic exam assessing vaginal depth, hernia or lumps in the groin (infants), family history
Radiological imaging: ultrasound or MRI showing lack of female reproductive organs and locating undescended testes
There is no cure for CAIS. Treatment generally focuses on managing symptoms and improving quality of life. This includes:
Estrogen replacement therapy (after puberty)
Vaginal dilation to lengthen cavity
Vaginoplasty if desired
Monitoring of or prophylactic removal of undescended testes (cancer risk)
Regular bone density scans
Psychological support
Genetic counseling for family members
The prognosis for individuals with CAIS is favorable with proper management and counseling. Patients have a normal life expectancy and can live active fulfilling lives. The main complications are osteoporosis, mental health burden, sexual dysfunction, infertility, and cancer. Testicular monitoring and or removal helps reduce the risk of cancer. Meanwhile regular bone scans, hormonal therapy, and calcium/vitamin D supplements can reduce the risk of osteoporosis. Counseling can help address issues of gender identity, body image, and sexual functioning. Assisted reproductive technologies may help those wishing to bear children.
Androgen Insensitivity Syndrome: Complete & Partial. (2021, December 14). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22199-androgen-insensitivity-syndrome
Fulare, S., Deshmukh, S., & Gupta, J. (2020). Androgen Insensitivity Syndrome: A rare genetic disorder. International Journal of Surgery Case Reports, 71, 371–373. https://doi.org/10.1016/j.ijscr.2020.01.032
Känsäkoski, J., Jääskeläinen, J., Jääskeläinen, T., Tommiska, J., Saarinen, L., Lehtonen, R., Hautaniemi, S., Frilander, M. J., Palvimo, J. J., Toppari, J., & Raivio, T. (2016). Complete androgen insensitivity syndrome caused by a deep intronic pseudoexon-activating mutation in the androgen receptor gene. Scientific Reports, 6(1), 32819. https://doi.org/10.1038/srep32819
I have CAIS, OCA2, SMA4, Asperger's Syndrome, and a variety of other things including more than one TBI and spinal injury. I have one brother with PAIS, and two with MAIS.
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.
Enrolling is easy.
After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.
Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.
Visit sanfordresearch.org/CoRDS to enroll.
Breast imaging radiologist
Board member and medical adviser to...
Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.
Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.
Created by Nimonic | Last updated 10 Sep 2016, 09:59 PM
Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.
FIND YOUR COMMUNITYOur rare disease resources include e-books and podcasts
Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.